NM_000311.5(PRNP):c.385A>G (p.Met129Val)

Base Editing (BE4max) via AAV9 delivery is a rationale-driven therapeutic strategy for Inherited Creutzfeldt-Jakob disease targeting the PRNP c.385A>G (p.Met129Val) variant (Pathogenic, missense variant, 3 prime UTR variant). The editing system (BE4max (cytosine base editor)) converts the pathogenic C to T (or G to A on the target strand), restoring the wild-type codon. Target tissue: CNS. Therapeutic goal: Correct or durably disrupt pathogenic PRNP alleles at the PRNP locus in the CNS to prevent prion replication and thereby halt or prevent the fatal neurodegeneration of inherited Creutzfeldt-Jakob dise. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity High (AAV pre-existing immunity).

1. Molecular basis: PRNP NM_000311.5(PRNP):c.385A>G (p.Met129Val) is classified as Pathogenic (ClinVar variation ID 13399). Molecular consequence: missense variant, 3 prime UTR variant. Protein change: M129V, D178N. 2. Epidemiology: Genetic (inherited) prion diseases, including inherited CJD, account for about 10–15% of all human prion diseases (PAPER-01, BIOMNI-07). Overall prion disease incidence is well below 1 per 100,000 person-years, qualifying as ultra-rare (WEB-07). Inherited CJD is an autosomal dominant disorder caused 3. Standard of care: Orphanet and EMA emphasise that there is no curative or disease-modifying therapy for CJD; management is purely supportive and palliative, focused on symptom control (pain, myoclonus, insomnia, anxiety) and comfort care (WEB-02, WEB-04, WEB-08). Patients are often rapidly transitioned to hospice or 4. Pipeline: EMA orphan designations and FDA orphan listings describe several experimental agents for CJD (e.g., pentamer formyl thiophene acetic acid/NSC500 and other small molecules), but none has progressed to marketing approval; NSC500 was only in preclinical evaluation at designation and no trials had start 5. CBE clinical validation: BE4max (Koblan et al. 2018) is the gold-standard cytosine base editor. Multiple CBE programs are in clinical development for liver and hematologic targets.

1. No published data specifically correcting PRNP c.385A>G (p.Met129Val) with Base Editing (BE4max); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 4. Delivery to CNS tissue remains a major translational bottleneck. Current vectors have limited transduction efficiency in these compartments. 4. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.